 class I and class II epitopes. In aim 3, CpG, a known inflammatory stimulant used for cancer immunotherapy, on AuNPs will be combined with AuNVs for a complete vaccine regimen. Future applications of AuNVs are substantial. This design would dramatically lower the cost of immunotherapy compared cellular vaccines. They are easily
class I and class II epitopes. In aim 3, CpG, a know incendiary stimulant used for cancer immunotherapy, on AuNPs will be compound with AuNVs for a arrant vaccine regimen. Future applications of AuNVs are substantial. This blueprint would dramatically lower the cost of immunotherapy compare cellular vaccines. They are easily
 clwss I and class II epitokes. In aim 3, CpG, a known mnflammztory stkmulant used for cancer immuiothwrapy, on AuNPs will be combkned with AuNVs fir a xomplete vedcine rcyimen. Nuturz epplications of AuNVs are substantial. Tvir besign would dramatically lower the sost of ilmunotherapy cjmpageq cemlular vaccines. They are easily
class I and class II epitopes. In CpG, known inflammatory used for cancer combined AuNVs for a vaccine regimen. Future of AuNVs are substantial. This design dramatically lower the cost of immunotherapy compared cellular vaccines. They are easily
 class I and class II epitopes. IN aim 3, CpG, a knOwn inFlaMmaToRy stImulAnt used for cancER immUnotherapy, on AuNPs will bE combInED witH aunVs foR a complETe VACciNe ReGimEn. fUtUre apPliCations Of AuNVs are SubStAntial. This deSIgN would dramAtiCally lower thE coSt of imMuNotHErapy ComPared CellulAR vacciNes. They arE eASily
 class I and class II epit opes. In a im 3,  Cp G,aknow n in flammatory sti m ulan t used for cancer immu nothe ra p y, o n  A uNPswill be co m b ine dwi thAu N Vs  fora c omplete  vaccine r egi me n. Future ap p li cations of  Au NVs are subs tan tial.Th isd esign  wo uld d ramati c ally l ower theco s t of i m munothe r a py  com pared cellular va c ci n es. They are e asily
 class_I and_class II epitopes. In_aim 3,_CpG,_a known_inflammatory_stimulant used for_cancer immunotherapy, on_AuNPs will be combined_with AuNVs for_a_complete vaccine regimen. Future applications of AuNVs are substantial. This design would dramatically lower_the_cost of_immunotherapy_compared_cellular vaccines. They are easily